Zhang Investor Law Announces Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. – ZYNE 

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) between March 11, 2019 and September 17, 2019 inclusive (the “Class Period”).

If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2019.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

To join the class action http://zhanginvestorlaw.com/join-action-form/?slug=zynerba-pharmaceuticals-inc&id=2057 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=zynerba-pharmaceuticals-inc&id=2057.  

According to the lawsuit,  throughout the Class Period, defendants and its senior executives presented false and misleading financial statements or omitted to disclose:  (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, Zynerba’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class has not been certified.  You may retain counsel of your choice.  You may take no action at this time and be an absent class member.  Your ability to obtain a recovery is not dependent upon being a lead plaintiff.  

Zhang Investor Law represents investors worldwide.  Attorney Advertising.  Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756